B-intervention	0	8	Pectoral
I-intervention	9	10	I
I-intervention	11	16	Block
O	17	21	Does
O	22	25	Not
O	26	33	Improve
B-condition	34	47	Postoperative
I-condition	48	57	Analgesia
O	58	63	After
O	64	70	Breast
O	71	77	Cancer
O	78	85	Surgery
O	85	86	:
O	87	88	A
O	89	99	Randomized
O	99	100	,
O	101	107	Double
O	107	108	-
O	108	113	Blind
O	113	114	,
O	115	119	Dual
O	119	120	-
O	120	128	Centered
O	129	139	Controlled
O	140	145	Trial
O	145	146	.

O	147	154	General
O	155	165	anesthesia
O	166	169	for
O	170	176	breast
O	177	184	surgery
O	185	188	may
O	189	191	be
O	192	204	supplemented
O	205	207	by
O	208	213	using
O	214	215	a
O	216	224	regional
O	225	235	anesthetic
O	236	245	technique
O	245	246	.

O	247	249	We
O	250	259	evaluated
O	260	263	the
O	264	272	efficacy
O	273	275	of
O	276	279	the
B-intervention	280	285	first
I-intervention	286	294	pectoral
I-intervention	295	300	nerve
I-intervention	301	306	block
I-intervention	307	308	(
I-intervention	308	312	Pecs
I-intervention	313	314	I
I-intervention	314	315	)
O	316	318	in
O	319	327	treating
O	328	341	postoperative
O	342	346	pain
O	347	352	after
O	353	359	breast
O	360	366	cancer
O	367	374	surgery
O	374	375	.

O	376	377	A
O	378	388	randomized
O	388	389	,
O	390	396	double
O	396	397	-
O	397	402	blind
O	402	403	,
O	404	408	dual
O	408	409	-
O	409	417	centered
O	417	418	,
O	419	426	placebo
O	426	427	-
O	427	437	controlled
O	438	443	trial
O	444	447	was
O	448	457	performed
O	457	458	.

B-total-participants	459	462	One
I-total-participants	463	470	hundred
I-total-participants	471	477	twenty
I-total-participants	477	478	-
I-total-participants	478	483	eight
B-eligibility	484	492	patients
I-eligibility	493	502	scheduled
I-eligibility	503	506	for
I-eligibility	507	517	unilateral
I-eligibility	518	524	breast
I-eligibility	525	531	cancer
I-eligibility	532	539	surgery
O	540	544	were
O	545	554	recruited
O	554	555	.

O	556	557	A
O	558	568	multimodal
O	569	578	analgesic
O	579	586	regimen
O	587	590	and
O	591	598	surgeon
O	598	599	-
O	599	611	administered
O	612	617	local
O	618	628	anesthetic
O	629	641	infiltration
O	642	646	were
O	647	651	used
O	652	655	for
O	656	659	all
O	660	668	patients
O	668	669	.

O	670	680	Ultrasound
O	680	681	-
O	681	687	guided
O	688	692	Pecs
O	693	694	I
O	695	698	was
O	699	708	performed
O	709	714	using
O	715	726	bupivacaine
O	727	729	or
O	730	736	saline
O	736	737	.

O	738	741	The
O	742	749	primary
O	750	757	outcome
O	758	761	was
O	762	765	the
B-outcome-Measure	766	773	patient
I-outcome-Measure	774	778	pain
I-outcome-Measure	779	784	score
O	785	786	(
O	786	795	numerical
O	796	802	rating
O	803	808	scale
O	809	810	[
O	810	813	NRS
O	813	814	]
O	814	815	)
O	816	818	in
O	819	822	the
O	823	831	recovery
O	832	836	unit
O	837	839	30
O	840	847	minutes
O	848	853	after
O	854	863	admission
O	864	866	or
O	867	871	just
O	872	878	before
O	879	882	the
O	883	891	morphine
O	892	906	administration
O	907	908	(
O	908	911	NRS
O	912	913	â‰¥
O	913	914	4
O	914	915	/
O	915	917	10
O	917	918	)
O	918	919	.

O	920	923	The
O	924	933	secondary
O	934	942	outcomes
O	943	947	were
B-outcome-Measure	948	961	postoperative
I-outcome-Measure	962	968	opioid
I-outcome-Measure	969	980	consumption
O	981	982	(
O	982	984	ie
O	984	985	,
O	986	988	in
O	989	992	the
O	993	1001	recovery
O	1002	1006	unit
O	1007	1010	and
O	1011	1016	after
O	1017	1019	24
O	1020	1025	hours
O	1025	1026	)
O	1026	1027	.

O	1028	1034	During
O	1035	1043	recovery
O	1043	1044	,
O	1045	1047	no
O	1048	1059	significant
O	1060	1070	difference
O	1071	1073	in
B-outcome	1074	1077	NRS
O	1078	1081	was
O	1082	1090	observed
O	1091	1098	between
O	1099	1102	the
O	1103	1114	bupivacaine
O	1115	1116	(
O	1116	1117	n
O	1118	1119	=
B-intervention-participants	1120	1122	62
O	1122	1123	,
B-iv-cont-median	1124	1125	3
I-iv-cont-median	1125	1126	.
I-iv-cont-median	1126	1127	0
O	1128	1129	[
O	1129	1130	1
O	1130	1131	.
O	1131	1132	0
O	1132	1133	-
O	1133	1134	4
O	1134	1135	.
O	1135	1136	0
O	1136	1137	]
O	1137	1138	)
O	1139	1142	and
O	1143	1150	placebo
O	1151	1152	(
O	1152	1153	n
O	1154	1155	=
B-control-participants	1156	1158	65
O	1158	1159	,
B-cv-cont-median	1160	1161	3
I-cv-cont-median	1161	1162	.
I-cv-cont-median	1162	1163	0
O	1164	1165	[
O	1165	1166	1
O	1166	1167	.
O	1167	1168	0
O	1168	1169	-
O	1169	1170	5
O	1170	1171	.
O	1171	1172	0
O	1172	1173	]
O	1173	1174	)
O	1175	1181	groups
O	1182	1183	(
O	1183	1184	P
O	1185	1186	=
O	1187	1188	0
O	1188	1189	.
O	1189	1191	55
O	1191	1192	)
O	1192	1193	.

O	1194	1201	However
O	1201	1202	,
O	1203	1206	the
B-outcome	1207	1210	NRS
O	1211	1214	was
O	1215	1228	statistically
O	1229	1242	significantly
O	1243	1252	different
O	1252	1253	,
O	1254	1262	although
O	1263	1266	not
O	1267	1277	clinically
O	1278	1289	significant
O	1289	1290	,
O	1291	1294	for
O	1295	1303	patients
O	1304	1314	undergoing
O	1315	1320	major
O	1321	1330	surgeries
O	1331	1332	(
O	1332	1344	mastectomies
O	1345	1347	or
O	1348	1361	tumorectomies
O	1362	1366	with
O	1367	1375	axillary
O	1376	1385	clearance
O	1385	1386	)
O	1387	1388	(
O	1388	1389	n
O	1390	1391	=
B-intervention-participants	1392	1394	29
O	1394	1395	,
B-iv-cont-median	1396	1397	3
I-iv-cont-median	1397	1398	.
I-iv-cont-median	1398	1399	0
O	1400	1401	[
O	1401	1402	0
O	1402	1403	.
O	1403	1404	0
O	1404	1405	-
O	1405	1406	4
O	1406	1407	.
O	1407	1408	0
O	1408	1409	]
O	1410	1412	vs
B-cv-cont-median	1413	1414	4
I-cv-cont-median	1414	1415	.
I-cv-cont-median	1415	1416	0
O	1417	1418	[
O	1418	1419	2
O	1419	1420	.
O	1420	1421	0
O	1421	1422	-
O	1422	1423	5
O	1423	1424	.
O	1424	1425	0
O	1425	1426	]
O	1426	1427	,
O	1428	1429	P
O	1430	1431	=
O	1432	1433	0
O	1433	1434	.
O	1434	1436	04
O	1436	1437	)
O	1437	1438	.

B-outcome	1439	1447	Morphine
I-outcome	1448	1459	consumption
I-outcome	1460	1466	during
I-outcome	1467	1475	recovery
O	1476	1479	did
O	1480	1483	not
O	1484	1490	differ
O	1491	1492	(
B-iv-cont-median	1492	1493	1
I-iv-cont-median	1493	1494	.
I-iv-cont-median	1494	1495	5
I-iv-cont-median	1496	1498	mg
O	1499	1500	[
O	1500	1501	0
O	1501	1502	.
O	1502	1503	0
O	1503	1504	-
O	1504	1505	6
O	1505	1506	.
O	1506	1507	0
O	1508	1510	mg
O	1510	1511	]
O	1512	1514	vs
B-cv-cont-median	1515	1516	3
I-cv-cont-median	1516	1517	.
I-cv-cont-median	1517	1518	0
I-cv-cont-median	1519	1521	mg
O	1522	1523	[
O	1523	1524	0
O	1524	1525	.
O	1525	1526	0
O	1526	1527	-
O	1527	1528	6
O	1528	1529	.
O	1529	1530	0
O	1531	1533	mg
O	1533	1534	]
O	1534	1535	,
O	1536	1537	P
O	1538	1539	=
O	1540	1541	0
O	1541	1542	.
O	1542	1544	20
O	1544	1545	)
O	1545	1546	,
O	1547	1553	except
O	1554	1556	in
O	1557	1560	the
B-outcome	1561	1566	major
I-outcome	1567	1574	surgery
I-outcome	1575	1583	subgroup
O	1584	1585	(
B-iv-cont-median	1585	1586	1
I-iv-cont-median	1586	1587	.
I-iv-cont-median	1587	1588	5
I-iv-cont-median	1589	1591	mg
O	1592	1593	[
O	1593	1594	0
O	1594	1595	.
O	1595	1596	0
O	1596	1597	-
O	1597	1598	6
O	1598	1599	.
O	1599	1600	0
O	1601	1603	mg
O	1603	1604	]
O	1605	1607	vs
B-cv-cont-median	1608	1609	6
I-cv-cont-median	1609	1610	.
I-cv-cont-median	1610	1611	0
I-cv-cont-median	1612	1614	mg
O	1615	1616	[
O	1616	1617	0
O	1617	1618	.
O	1618	1619	0
O	1619	1620	-
O	1620	1622	12
O	1622	1623	.
O	1623	1624	0
O	1625	1627	mg
O	1627	1628	]
O	1628	1629	,
O	1630	1631	P
O	1632	1633	=
O	1634	1635	0
O	1635	1636	.
O	1636	1639	016
O	1639	1640	)
O	1640	1641	.

B-outcome	1642	1656	Intraoperative
I-outcome	1657	1667	sufentanil
O	1668	1671	and
B-outcome	1672	1682	cumulative
I-outcome	1683	1691	morphine
I-outcome	1692	1703	consumption
O	1704	1706	up
O	1707	1709	to
O	1710	1712	24
O	1713	1718	hours
O	1719	1722	did
O	1723	1726	not
O	1727	1733	differ
O	1734	1741	between
O	1742	1745	the
O	1746	1747	2
O	1748	1754	groups
O	1754	1755	.

O	1756	1761	Three
O	1762	1770	patients
O	1771	1782	experienced
B-outcome	1783	1796	complications
O	1797	1804	related
O	1805	1807	to
O	1808	1811	the
O	1812	1816	Pecs
O	1817	1818	I
O	1818	1819	.
O	1820	1824	Pecs
O	1825	1826	I
O	1827	1829	is
O	1830	1833	not
O	1834	1840	better
O	1841	1845	than
O	1846	1847	a
O	1848	1854	saline
O	1855	1862	placebo
O	1863	1865	in
O	1866	1869	the
O	1870	1878	presence
O	1879	1881	of
O	1882	1892	multimodal
O	1893	1902	analgesia
O	1903	1906	for
O	1907	1913	breast
O	1914	1920	cancer
O	1921	1928	surgery
O	1928	1929	.

O	1930	1937	However
O	1937	1938	,
O	1939	1942	its
O	1943	1947	role
O	1948	1950	in
O	1951	1959	extended
O	1960	1961	(
O	1961	1966	major
O	1966	1967	)
O	1968	1974	breast
O	1975	1982	surgery
O	1983	1986	may
O	1987	1994	warrant
O	1995	2002	further
O	2003	2016	investigation
O	2016	2017	.

O	2018	2022	This
O	2023	2028	study
O	2029	2032	was
O	2033	2043	registered
O	2044	2046	at
O	2047	2061	ClinicalTrials
O	2061	2062	.
O	2062	2065	gov
O	2065	2066	,
O	2067	2077	identifier
O	2078	2089	NCT01670448
O	2089	2090	.
